![Anne Erickson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Anne Erickson
Corporate Officer/Principal chez
SAVARA INC.
Fortune : 2 M $ au 30/09/2026
Profil
Anne C.
Erickson is currently Chief Business Officer at Savara, Inc., a position held since 2023.
Formerly, Ms. Erickson was Executive Director-Investor & Media Relations at Halozyme Therapeutics, Inc. Ms. Erickson completed undergraduate studies at the University of Minnesota.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SAVARA, INC. 0,18% | 14/12/2025 | 371 712 ( 0,18% ) | 2 M $ | 30/09/2026 |
Postes actifs de Anne Erickson
| Sociétés | Poste | Début |
|---|---|---|
| SAVARA INC. | Corporate Officer/Principal | 01/10/2022 |
Anciens postes connus de Anne Erickson
| Sociétés | Poste | Fin |
|---|---|---|
| HALOZYME THERAPEUTICS, INC. | Investor Relations Contact | - |
Formation de Anne Erickson
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
28
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Halozyme Therapeutics, Inc.
 Halozyme Therapeutics, Inc. BiotechnologyHealth Technology Engages in the development and commercialization of recombinant human enzymes for the infertility, ophthalmology & oncology markets | Health Technology |
University of Minnesota
 University of Minnesota Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Savara, Inc.
 Savara, Inc. Pharmaceuticals: MajorHealth Technology Develops pharmaceuticals to treat respiratory diseases | Health Technology |
